Sort by
Refine Your Search
-
About us The UCL Cancer Institute is the hub for basic biological and translational cancer research at University College London, one of the world's leading universities. The Institute draws
-
on the mechanism(s) and function(s) of mitochondrial segregation in C. elegans using biochemical, molecular, genetic and imaging-based methods, with the goal of advancing our understanding of this process as
-
of manufacturing. We have identified an opportunity to combine continuous microfluidic (µF) process models, process analytical technology (PAT) and machine learning (ML) to achieve a paradigm shift in bioprocess
-
of manufacturing. We have identified an opportunity to combine continuous microfluidic (µF) process models, process analytical techn ology (PAT) and machine learning (ML) to achieve a paradigm shift in bioprocess
-
surgical planning. The successful candidate will join a dynamic clinical trial team working in collaboration with the UCL CRC and the joint UCLH Endocrinology and Endocrine Surgery Departments, both of which
-
of manufacturing. We have identified an opportunity to combine continuous microfluidic (µF) process models, process analytical techn ology (PAT) and machine learning (ML) to achieve a paradigm shift in bioprocess
-
About us The UCL Centre for Radiopharmaceutical Chemistry (CRC) is a multidisciplinary research centre dedicated to the development and clinical translation of novel biomedical imaging agents
-
biomarker collection and MRI imaging. Both the EJS ACT-PD Trial and Initiative are led by Professor Camille Carroll (Newcastle University, Co-Chief investigator) and Professor Thomas Foltynie (UCL, Co-Chief
-
bronchoscopy programmes for patients with premalignant changes in their lung. We offer a rapid diagnostics clinic in the UCLH Macmillan Cancer Centre, which includes state-of-the-art imaging with computed
-
outcome measures, wet biomarker collection and MRI imaging. Both the EJS ACT-PD Trial and Initiative are led by Professor Camille Carroll (Newcastle University, Co-Chief investigator) and Professor Thomas